Singh et al. (2016) observed that knocking out BC200 by CRISPR/Cas9 reduced cell proliferation in vitro and tumor growth in a xenograft mouse model, and increased apoptosis as well as the levels of the short, proapoptotic form of Bcl-x (Bcl-xS) over the long, antiapoptotic form (Bcl-xL). The gene discussed is BCYRN1; the disease is neoplasm.